	US 12,187,805 B2
	Type-II VNAR polypeptides which bind human TfR-1, encoding nucleic acids thereof and method of use thereof
Pawel Stocki, Hertfordshire (GB); Jaroslaw Michal Szary, Cambridge (GB); Krzysztof Bartlomiej Wicher, Cambridge (GB); Laura Thei, Cambridge (GB); Julia Lynn Rutkowski, Bryn Mawr, PA (US); Mykhaylo Demydchuk, Cambridge (GB); and Shu-Fen Coker, Amersham (GB)
Assigned to Ossianix, Inc., Philadelphia, PA (US)
Appl. No. 18/033,600
Filed by OSSIANIX, INC, Philadelphia, PA (US)
PCT Filed Nov. 9, 2021, PCT No. PCT/US2021/058661 § 371(c)(1), (2) Date Apr. 25, 2023, PCT Pub. No. WO2022/103769, PCT Pub. Date May 19, 2022.
Claims priority of provisional application 63/234,210, filed on Aug. 17, 2021.
Claims priority of provisional application 63/112,314, filed on Nov. 11, 2020.
Prior Publication US 2024/0026022 A1, Jan. 25, 2024
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C12N 15/63 (2006.01); G01N 33/68 (2006.01)

CPC C07K 16/2881 (2013.01) [A61P 35/00 (2018.01); C12N 15/63 (2013.01); G01N 33/68 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/569 (2013.01); C07K 2317/77 (2013.01)]

23 Claims

1. A Type II VNAR polypeptide which comprises a VNAR domain capable of specifically binding to human TfR-1 without substantially interfering with transferrin binding to and/or transport by human TfR-1, wherein said VNAR domain is represented by the formula, from N to C terminus, FW1-CDR1-FW2-HV2-FW2′-HV4-FW3-CDR3-FW4, and wherein the CDR1 region has an amino acid sequence of DSNCALSS (SEQ ID NO. 1) and the CDR3 region has an amino acid sequence of VVGTWCMSWRDV (SEQ ID NO. 2).